Nicox, Rapid Pathogen Screening deal
Rapid granted NicOx exclusive, worldwide rights to commercialize several ophthalmic diagnostics.The deal includes AdenoPlus adenoviral conjunctivitis diagnostic and two diagnostics in development - RPS-AP for detecting adenoviral and allergic conjunctivitis and RPS-OH to diagnose ocular herpes. In the U.S., NicOx is limited to commercializing to eye care professionals. Rapid retains rights to commercialize the tests in the U.S. to primary and urgent care professionals. NicOx has an option to negotiate for exclusive, worldwide rights to an additional product based on Rapid meeting certain milestones. NicOx will pay a license and option fee to Rapid, which is eligible for milestones and royalties. NicOx will also pay half of the development costs for the development-stage diagnostics. Details were not disclosed. ...